Puppo Francesco, Murdaca Giuseppe, Ghio Massimo, Indiveri Francesco
Department of Internal Medicine (Di.M.I.), University of Genoa, Viale Benedetto XV, n.6-16132 Genova, Italy.
Autoimmun Rev. 2005 Nov;4(8):537-41. doi: 10.1016/j.autrev.2005.04.016.
This article reviews the role of emerging biologic drugs for the treatment of rheumatoid arthritis (RA). Besides anti-tumor necrosis factor (TNF)-alpha and anti-interleukin (IL)-1 agents (Infliximab, Adalimumab, Etanercept and Anakinra) whose clinical efficacy is now established, new drugs have been proposed for the therapy of rheumatoid arthritis patients not responding to conventional treatments. These approaches include the blockade of B-cell activity with anti-CD20 monoclonal antibody (Rituximab) and the inhibition of T-cell activation with fusion protein CTLA4Ig. Moreover, promising results have been obtained in animal models utilizing suppressors of cytokine signaling (SOCS) and dominant-negative TNF variants to inactivate TNF signaling.
本文综述了新型生物药物在类风湿关节炎（RA）治疗中的作用。除了临床疗效已得到证实的抗肿瘤坏死因子（TNF）-α和抗白细胞介素（IL）-1药物（英夫利昔单抗、阿达木单抗、依那西普和阿那白滞素）外，还提出了用于治疗对传统治疗无反应的类风湿关节炎患者的新药。这些方法包括用抗CD20单克隆抗体（利妥昔单抗）阻断B细胞活性以及用融合蛋白CTLA4Ig抑制T细胞活化。此外，在动物模型中利用细胞因子信号转导抑制因子（SOCS）和显性负性TNF变体使TNF信号失活已取得了有前景的结果。
